A Phase 3 interventional study of Dulaglutide and Placebo in Cardiovascular Disease and Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 301 sites in 25 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2019-10-08.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this trial is to assess whether dulaglutide can reduce major cardiovascular events and other serious outcomes in persons with type 2 diabetes, when added to their anti-hyperglycemic regimen.
5,370 studies on the registry are indexed under Cardiovascular Diseases; 938 are open to participants now.
This study's enrollment of 9,901 is above the median of 100 across 3,084 interventional studies indexed under Cardiovascular Diseases.
Browse Cardiovascular Diseases studies →Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Administered once weekly, subcutaneously
Drug: Dulaglutide
Administered once weekly, subcutaneously
Drug: Placebo
Administered subcutaneously
Also known as: LY2189265
Administered subcutaneously
Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome)
The time from randomization to first occurrence of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke (a composite endpoint) was evaluated using time-to-event analysis. The primary analysis model was a Cox proportional hazards regression model for the time to the first occurrence of a primary endpoint event, with treatment as a fixed effect using the intent-to-treat population. The number of participants who experienced a primary cardiovascular (CV) endpoint event is presented.
Time frame: From randomization to first occurrence or death from any cause or study completion (Median Follow-Up of 5.4 Years)
Number of Participants Who Experienced an Event for Time to First Occurrence After Randomization of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke, Individually
The time from randomization to first occurrence of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke (individually) was evaluated using time-to-event analysis via the Cox proportional hazards regression model where response equals treatment. Death from CV causes is defined as a death resulting from an acute myocardial infarction (MI), sudden cardiac death, death due to heart failure, death due to stroke, or death due to other CV causes. The number of participants who experienced an event is presented.
Time frame: From randomization to first occurrence or study completion (Median Follow-Up of 5.4 Years)
Number of Participants Who Experienced an Event for Time to All-cause Mortality
The time to all-cause mortality was evaluated using time-to-event analysis via the Cox proportional hazards regression model where response equals treatment. The number of participants who experienced an event is presented.
Time frame: From randomization to study completion (Median Follow-Up of 5.4 Years)
Number of Participants Who Experienced an Event for Time to First Occurrence After Randomization of the Composite Microvascular Endpoint
The time from randomization to first occurrence of the composite microvascular endpoint was evaluated using time-to-event analysis via the Cox proportional hazards regression model where response equals treatment. The composite microvascular endpoint is defined as diabetic retinopathy requiring laser therapy, vitrectomy, or anti-vascular endothelial growth factor therapy (VEGF), clinical proteinuria, a greater than equal ≥ 30% decline in estimated glomerular filtration rate, or need for chronic renal replacement therapy. The number of participants who experienced the composite microvascular endpoint event is presented.
Time frame: From randomization to first occurrence or study completion (Median Follow-Up of 5.4 Years)
Number of Participants Who Experienced An Event for Time to First Occurrence After Randomization of Heart Failure Requiring Hospitalization or an Urgent Heart Failure Clinic Visit
The time to first occurrence after randomization of heart failure requiring hospitalization or an urgent heart failure clinic visit was evaluated using time-to-event analysis via the Cox proportional hazards regression model where response equals treatment. The number of participants who experienced an event is presented.
Time frame: From randomization to first occurrence or study completion (Median Follow-Up of 5.4 Years)
Number of Participants Who Experienced an Event for Time to First Occurrence After Randomization of First Hospitalization for Unstable Angina
Time to first occurrence after randomization of first hospitalization for unstable angina was evaluated using time-to-event analysis via the Cox proportional hazards regression model where response equals treatment. The number of participants who experienced an event is presented.
Time frame: From randomization to first occurrence or study completion (Median Follow-Up of 5.4 Years)
| Milestone | Placebo | Dulaglutide |
|---|---|---|
| Started | 4952 | 4949 |
| Received at least one dose of study drug | 4949 | 4943 |
| Completed | 4935 | 4932 |
| Not completed | 17 | 17 |
| Withdrew: Lost to follow-up | 0 | 5 |
| Withdrew: Withdrawal by subject | 10 | 5 |
| Withdrew: Physician decision | 2 | 0 |
| Withdrew: Sponsor decision | 5 | 7 |
The time from randomization to first occurrence of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke (a composite endpoint) was evaluated using time-to-event analysis. The primary analysis model was a Cox proportional hazards regression model for the time to the first occurrence of a primary endpoint event, with treatment as a fixed effect using the intent-to-treat population. The number of participants who experienced a primary cardiovascular (CV) endpoint event is presented.
| Participants | Placebo | Dulaglutide |
|---|---|---|
| Number of Participants Who Experienced an Event For Time, From Randomization to First Occurrence of Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke (a Composite Cardiovascular Outcome) | 663 | 594 |
The time from randomization to first occurrence of cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke (individually) was evaluated using time-to-event analysis via the Cox proportional hazards regression model where response equals treatment. Death from CV causes is defined as a death resulting from an acute myocardial infarction (MI), sudden cardiac death, death due to heart failure, death due to stroke, or death due to other CV causes. The number of participants who experienced an event is presented.
| Participants | Placebo | Dulaglutide |
|---|---|---|
| Death from CV causes | 346 | 317 |
| Nonfatal MI | 212 | 205 |
| Nonfatal stroke | 175 | 135 |
The time to all-cause mortality was evaluated using time-to-event analysis via the Cox proportional hazards regression model where response equals treatment. The number of participants who experienced an event is presented.
| Participants | Placebo | Dulaglutide |
|---|---|---|
| Number of Participants Who Experienced an Event for Time to All-cause Mortality | 592 | 536 |
The time from randomization to first occurrence of the composite microvascular endpoint was evaluated using time-to-event analysis via the Cox proportional hazards regression model where response equals treatment. The composite microvascular endpoint is defined as diabetic retinopathy requiring laser therapy, vitrectomy, or anti-vascular endothelial growth factor therapy (VEGF), clinical proteinuria, a greater than equal ≥ 30% decline in estimated glomerular filtration rate, or need for chronic renal replacement therapy. The number of participants who experienced the composite microvascular endpoint event is presented.
| Participants | Placebo | Dulaglutide |
|---|---|---|
| Number of Participants Who Experienced an Event for Time to First Occurrence After Randomization of the Composite Microvascular Endpoint | 1241 | 1099 |
The time to first occurrence after randomization of heart failure requiring hospitalization or an urgent heart failure clinic visit was evaluated using time-to-event analysis via the Cox proportional hazards regression model where response equals treatment. The number of participants who experienced an event is presented.
| Participants | Placebo | Dulaglutide |
|---|---|---|
| Number of Participants Who Experienced An Event for Time to First Occurrence After Randomization of Heart Failure Requiring Hospitalization or an Urgent Heart Failure Clinic Visit | 226 | 213 |
Time to first occurrence after randomization of first hospitalization for unstable angina was evaluated using time-to-event analysis via the Cox proportional hazards regression model where response equals treatment. The number of participants who experienced an event is presented.
| Participants | Placebo | Dulaglutide |
|---|---|---|
| Number of Participants Who Experienced an Event for Time to First Occurrence After Randomization of First Hospitalization for Unstable Angina | 77 | 88 |
Collected over From Randomization to Study Completion (Up to 7 Years). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | 592/4,949 (12%) | 2,044/4,949 (41.3%) | 3,363/4,949 (68%) |
| Dulaglutide | 536/4,943 (10.8%) | 1,991/4,943 (40.3%) | 3,574/4,943 (72.3%) |
| Event | Placebo | Dulaglutide |
|---|---|---|
| PneumoniaInfections and infestations | 151/4949 | 135/4943 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 110/4949 | 136/4943 |
| FallInjury, poisoning and procedural complications | 124/4949 | 110/4943 |
| Cardiac failureCardiac disorders | 104/4949 | 78/4943 |
| Atrial fibrillationCardiac disorders | 62/4949 | 90/4943 |
| HypoglycaemiaMetabolism and nutrition disorders | 72/4949 | 62/4943 |
| HyperglycaemiaMetabolism and nutrition disorders | 67/4949 | 46/4943 |
| Acute kidney injuryRenal and urinary disorders | 67/4949 | 61/4943 |
| Urinary tract infectionInfections and infestations | 61/4949 | 64/4943 |
| Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 33/2667 | 33/2640 |
| Event | Placebo | Dulaglutide |
|---|---|---|
| NauseaGastrointestinal disorders | 269/4949 | 735/4943 |
| DiarrhoeaGastrointestinal disorders | 436/4949 | 665/4943 |
| NasopharyngitisInfections and infestations | 535/4949 | 564/4943 |
| Urinary tract infectionInfections and infestations | 517/4949 | 545/4943 |
| Back painMusculoskeletal and connective tissue disorders | 416/4949 | 447/4943 |
| HypertensionVascular disorders | 432/4949 | 345/4943 |
| BronchitisInfections and infestations | 421/4949 | 408/4943 |
| HypoglycaemiaMetabolism and nutrition disorders | 354/4949 | 413/4943 |
| Upper respiratory tract infectionInfections and infestations | 407/4949 | 368/4943 |
| InfluenzaInfections and infestations | 404/4949 | 369/4943 |
All randomized participants
| Age, Categorical(Participants) | Placebo | Dulaglutide | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 2315 | 2330 | 4645 |
| >=65 years | 2637 | 2619 | 5256 |
| Age, Continuous(years) | Placebo | Dulaglutide | Total |
|---|---|---|---|
| Mean | 66.2 ± 6.5 | 66.2 ± 6.5 | 66.2 ± 6.5 |
| Sex: Female, Male(Participants) | Placebo | Dulaglutide | Total |
|---|---|---|---|
| Female | 2283 | 2306 | 4589 |
| Male | 2669 | 2643 | 5312 |
| Ethnicity (NIH/OMB)(Participants) | Placebo | Dulaglutide | Total |
|---|---|---|---|
| Hispanic or Latino | 64 | 60 | 124 |
| Not Hispanic or Latino | 402 | 400 | 802 |
| Unknown or Not Reported | 4486 | 4489 | 8975 |
| Race (NIH/OMB)(Participants) | Placebo | Dulaglutide | Total |
|---|---|---|---|
| American Indian or Alaska Native | 543 | 549 | 1092 |
| Asian | 218 | 216 | 434 |
| Native Hawaiian or Other Pacific Islander | 22 | 12 | 34 |
| Black or African American | 346 | 331 | 677 |
| White | 3744 | 3754 | 7498 |
| More than one race | 79 | 87 | 166 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Placebo | Dulaglutide | Total |
|---|---|---|---|
| United States | 475 | 468 | 943 |
| Czechia | 107 | 106 | 213 |
| Russia | 50 | 51 | 101 |
| South Korea | 62 | 60 | 122 |
| Sweden | 117 | 119 | 236 |
| Latvia | 39 | 39 | 78 |
| Brazil | 137 | 138 | 275 |
| Poland | 305 | 303 | 608 |
| Chile | 64 | 64 | 128 |
| Bulgaria | 50 | 51 | 101 |
| Lithuania | 52 | 53 | 105 |
| Colombia | 392 | 393 | 785 |
| Argentina | 698 | 697 | 1395 |
| Romania | 544 | 541 | 1085 |
| Hungary | 113 | 110 | 223 |
| United Kingdom | 65 | 71 | 136 |
| Spain | 62 | 65 | 127 |
| New Zealand | 119 | 115 | 234 |
| Canada | 564 | 564 | 1128 |
| Taiwan | 13 | 13 | 26 |
| South Africa | 369 | 372 | 741 |
| Mexico | 219 | 219 | 438 |
| Australia | 44 | 44 | 88 |
| Germany | 292 | 293 | 585 |
Showing the first 100 of 301 sites across 25 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com. This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting.
Access criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
Data sharing details ↗ · vivli.org
Ran from Jul 2011 to primary completion in Aug 2018, 84 months.
Results were first posted in Oct 2019, 1 year 1 month after primary completion.
Of 42 industry-sponsored phase 3 interventional studies under Cardiovascular Diseases, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 79. This study's 84 months is above that.
Counting every sponsor, half of 82 studies reached it within 57 months; a quarter within 34 and three quarters within 83.
Cardiovascular Diseases covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dulaglutide